%0 Journal Article %T Treatment patterns and comparative effectiveness in elderly acute myeloid leukemia patients (age 70 years or older): the Lyon-university hospital experience %+ Service d’Hématologie [Centre Hospitalier Lyon Sud - HCL] %+ Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL) %+ Hospices Civils de Lyon (HCL) %+ Virologie et pathogenèse virale (VPV) %+ Institut Mondor de Recherche Biomédicale (IMRB) %A Heiblig, M. %A Le, Jeune C. %A Elhamri, M. %A Balsat, M. %A Tigaud, I. %A Plesa, A. %A Barraco, F. %A Labussiere, H. %A Ducastelle, S. %A Nicolini, F. %A Wattel, E. %A Salles, Gilles %A Thomas, X. %< avec comité de lecture %@ 1042-8194 %J Leukemia & lymphoma %I Taylor & Francis %V 58 %P 110-117 %8 2017-01 %D 2017 %R 10.1080/10428194.2016.1180688 %M 27184036 %K Cytogenetics %K cytology %K France %K immunology %K Laboratories %K Leukemia %K Patients %K Population %K Survival %K Survival Rate %K therapy %Z Life Sciences [q-bio]/CancerJournal articles %X The treatment of very elderly patients (\textgreater/=70 years) with acute myeloid leukemia remains controversial. We present here 302 patients seen over a 14-year period in order to understand the real-world treatment patterns and outcomes in this patient population. Less than 25% of patients achieved a complete remission. The median overall survival was 12.4, 11.5 and 2.6 months, with a 3-year rates of 27%, 17% and 6%, for non-acute promyelocytic leukemia patients receiving intensive chemotherapy, lower-intensity therapy or best supportive care (BSC), respectively. In all ages, results were not significantly different among patients receiving low-intensity therapy and intensive chemotherapy, but significantly worse in those treated with BSC only. Similarly, intensive chemotherapy and low-intensity therapy gave better survival rates than BSC in patients with favorable- or intermediate-risk cytogenetics and in those with unfavorable cytogenetics (p \textless 0.0001 and p = 0.04, respectively) %G English %L hal-01795720 %U https://univ-lyon1.hal.science/hal-01795720 %~ HCL %~ CNRS %~ UNIV-LYON1 %~ CHLS %~ IMRB %~ UPEC %~ CRCL %~ UDL %~ UNIV-LYON